Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Actinium Pharmaceuticals Inc (ATNM)

Actinium Pharmaceuticals Inc (ATNM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 153,261
  • Shares Outstanding, K 13,587
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,900 K
  • 60-Month Beta 1.34
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.06
Trade ATNM with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.46
  • Number of Estimates 2
  • High Estimate -0.33
  • Low Estimate -0.59
  • Prior Year -1.20
  • Growth Rate Est. (year over year) +61.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.40 +34.29%
on 09/24/20
12.36 -8.77%
on 10/19/20
+2.37 (+26.60%)
since 09/23/20
3-Month
6.84 +64.91%
on 09/04/20
19.47 -42.06%
on 07/27/20
-3.57 (-24.04%)
since 07/23/20
52-Week
4.71 +139.49%
on 04/22/20
19.47 -42.06%
on 07/27/20
+4.76 (+73.03%)
since 10/23/19

Most Recent Stories

More News
Actinium Pharmaceuticals (ATNM) Gains But Lags Market: What You Should Know

In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $11.82, marking a +0.34% move from the previous day.

ATNM : 11.28 (-4.57%)
Promising New Cancer Treatments Advancing Through The Pipeline In Over $200 Billion Dollar Drug Market

, /PRNewswire/ -- Cancer immunotherapy has emerged as a new avenue for revenue generation for pharmaceutical companies. Adverse effects, such as recurrence of cancer and organ failure, associated with...

ATNM : 11.28 (-4.57%)
AZN : 52.00 (+0.08%)
BMY : 60.13 (-1.04%)
MRK : 79.83 (+0.78%)
NWBO : 1.9800 (+4.21%)
Actinium Pharmaceuticals, Inc. Awarded Grant by National Institutes of Health to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-Cell Therapy

, /PRNewswire/ --   (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that the National Institutes of Health has awarded Actinium a Small Business Technology Transfer grant to support...

ATNM : 11.28 (-4.57%)
Actinium Pharmaceuticals Inc Up 27.4% Since SmarTrend Uptrend Call (ATNM)

SmarTrend identified an Uptrend for Actinium Pharmaceuticals Inc (AMEX:ATNM) on September 16th, 2020 at $9.46. In approximately 1 month, Actinium Pharmaceuticals Inc has returned 27.38% as of today's...

ATNM : 11.28 (-4.57%)
Actinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research Facility to Enhance Development of Next Generation Antibody Radiation Conjugates Leveraging Its Proprietary AWE Platform

, /PRNewswire/ --  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced the launch of its new research and development lab facility in .  This new research facility expands Actinium's...

ATNM : 11.28 (-4.57%)
Actinium Pharmaceuticals (ATNM) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Actinium Pharmaceuticals (ATNM) closed at $10.15, marking a +1.2% move from the previous day.

ATNM : 11.28 (-4.57%)
Actinium Pharmaceuticals, Inc. Announces Clinical Trial Site Expansion in its Multi-Center Phase 1/2 Actimab-A Venetoclax Combination Trial

, /PRNewswire/ --   (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that the and the Ochsner Clinic in are now active trial sites in its Phase 1/2 Actimab-A venetoclax combination...

ATNM : 11.28 (-4.57%)
Actinium Pharmaceuticals (ATNM) Dips More Than Broader Markets: What You Should Know

Actinium Pharmaceuticals (ATNM) closed the most recent trading day at $9.18, moving -1.71% from the previous trading session.

ATNM : 11.28 (-4.57%)
Actinium Pharmaceuticals Successfully Completes First Dosing Cohort in the Phase 1 Study of Actimab-A and Venetoclax Combination Therapy in Relapsed/Refractory AML Patients

, /PRNewswire/ --   (NYSE AMERICAN: ATNM) (the "Company" or "Actinium") today announced that it has successfully completed the first dosing cohort in the Actimab-A and venetoclax combination, multi-center...

ATNM : 11.28 (-4.57%)
Actinium Pharmaceuticals Announces Successful Completion of Planned Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed/Refractory AML at Medical College of Wisconsin

, /PRNewswire/ --   (NYSE AMERICAN: ATNM) (the "Company" or "Actinium") today provided an update on the Actimab-A CLAG-M combination Phase 1 trial being conducted at the ("MCW") in patients with Relapsed...

ATNM : 11.28 (-4.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation.

See More

Key Turning Points

2nd Resistance Point 12.20
1st Resistance Point 11.74
Last Price 11.28
1st Support Level 10.99
2nd Support Level 10.70

See More

52-Week High 19.47
Fibonacci 61.8% 13.83
Fibonacci 50% 12.09
Last Price 11.28
Fibonacci 38.2% 10.35
52-Week Low 4.71

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar